ibs-smart is an ELISA blood test that measures the levels of two antibodies known to be elevated in patients with post-infectious irritable bowel syndrome (IBS).
The test offers physicians an optimized diagnosis protocol for diarrhea-predominant and mixed-type irritable bowel syndrome (IBS-D and IBS-M).
For the 10-15% of the worldwide population that suffers from IBS, ibs-smart can offer a clear diagnosis, prevent potentially unnecessary invasive procedures, and set a faster path to treatment.
The test is based on a 2,500-patient study conducted at Cedars-Sinai. Gemelli Biotech has the exclusive license from Cedars-Sinai to bring this test to market and continues to innovate the test in alignment with ongoing research into the pathophysiology of IBS.
To learn more, visit: www.ibssmart.com
The trio-smart breath test measures the levels of hydrogen, methane, and hydrogen sulfide in a patient’s breath to determine if any are elevated abnormally.
trio-smart aids in the in the identification of small intestinal bacterial overgrowth (SIBO), intestinal methanogenic overgrowth (IMO) and excess hydrogen sulfide.
Using best-in-class breath testing technology, trio-smart is the only breath test to measure hydrogen sulfide, which correlates with diarrhea.
trio-smart uses a proprietary sealed breath collection system for more accurate sample collection and has a more precise gas measurement device, significantly reducing the risk of false positives and false negatives.
To learn more, visit www.triosmartbreath.com